WALTHAM, Mass., Sept. 13, 2017 /PRNewswire/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO), the world leader in serving science,
announced the expiration of the subsequent offering period of its
previously announced tender offer to purchase all of the
outstanding ordinary shares of Patheon N.V. The company completed
the acquisition of Patheon on August 29,
2017.
The subsequent offering period expired at 12:01 a.m., New York
City time, on September 13,
2017. Based on information provided by American Stock
Transfer & Trust Company, LLC, the depositary for the
tender offer, a total of 143,781,162 Patheon ordinary shares
(including Patheon ordinary shares tendered during the initial
offering period), representing approximately 99% of the outstanding
Patheon ordinary shares, had been validly tendered as of
12:01 a.m., New York City time, on September 13,
2017. Thermo Fisher's wholly owned
subsidiary, Thermo Fisher (CN)
Luxembourg S.à r.l., immediately accepted for payment and has
promptly paid (or will promptly pay) for all ordinary shares that
were validly tendered during the subsequent offering period in the
same form and amount as the offer consideration paid in the initial
offering period.
Thermo Fisher plans to initiate a
statutory proceeding before the Enterprise Chamber
(Ondernemingskamer) of the Amsterdam Court of Appeals (Gerechtshof
Amsterdam) for the compulsory acquisition
(uitkoopprocedure) of all remaining non-tendered shares as
provided by Dutch law in accordance with Section 2:92a or
Section 2:201a of the Dutch Civil Code. In such a proceeding,
the Enterprise Chamber will determine a cash price to be paid for
such shares (which may be greater, equal to or less than the offer
consideration).
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in
serving science, with revenues of more than $20 billion and approximately 65,000 employees
globally. Our mission is to enable our customers to make the world
healthier, cleaner and safer. We help our customers accelerate life
sciences research, solve complex analytical challenges, improve
patient diagnostics, deliver medicines to market and increase
laboratory productivity. Through our premier brands – Thermo
Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and
Unity Lab Services – we offer an unmatched combination of
innovative technologies, purchasing convenience and comprehensive
services. For more information, please visit
www.thermofisher.com.
Forward-Looking Statements
This communication contains forward-looking statements that
involve a number of risks and uncertainties. Words such as
"believes," "anticipates," "plans," "expects," "seeks,"
"estimates," and similar expressions are intended to identify
forward-looking statements, but other statements that are not
historical facts may also be deemed to be forward-looking
statements. Important factors that could cause actual results to
differ materially from those indicated by forward-looking
statements include risks and uncertainties relating to: the need to
develop new products and adapt to significant technological change;
implementation of strategies for improving growth; general economic
conditions and related uncertainties; dependence on customers'
capital spending policies and government funding policies; the
effect of exchange rate fluctuations on international operations;
use and protection of intellectual property; the effect of changes
in governmental regulations; and the effect of laws and regulations
governing government contracts, as well as the possibility that
expected benefits related to recent and pending acquisitions,
including the acquisition of Patheon, may not materialize as
expected; difficulty retaining key employees; and our ability to
successfully implement integration strategies or to achieve
expected synergies and operating efficiencies within the expected
time-frames or at all. Additional important factors that could
cause actual results to differ materially from those indicated by
such forward-looking statements are set forth in Thermo Fisher's Annual Report on Form 10-K for
the year ended December 31, 2016,
which is on file with the SEC and available in the "Investors"
section of Thermo Fisher's website,
ir.thermofisher.com, under the heading "SEC Filings," and in any
subsequent Quarterly Reports on Form 10-Q and other documents
Thermo Fisher files with the SEC,
and in Patheon's Annual Report on Form 10-K for the year ended
October 31, 2016 and its subsequent
Quarterly Reports on Form 10-Q, including its Quarterly Report on
Form 10-Q for the quarter ended January 31,
2017 and its Quarterly Report on Form 10-Q for the quarter
ended April 30, 2017, each of which
is on file with the SEC and available in the "Investor Relations"
section of Patheon's website, ir.patheon.com, under the heading
"SEC Filings," and in other documents Patheon files with the SEC.
While Thermo Fisher may elect to
update forward-looking statements at some point in the future,
Thermo Fisher specifically disclaims
any obligation to do so, even if estimates change and, therefore,
you should not rely on these forward-looking statements as
representing Thermo Fisher's views
as of any date subsequent to today.
Thermo Fisher Scientific Inc.
Media Contact Information:
Karen Kirkwood
Phone: 781-622-1306
E-mail: karen.kirkwood@thermofisher.com
Website: www.thermofisher.com
or
Investor Contact Information:
Ken Apicerno
Phone: 781-622-1294
E-mail: ken.apicerno@thermofisher.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-subsequent-offering-period-of-tender-offer-following-acquisition-of-patheon-nv-300518681.html
SOURCE Thermo Fisher Scientific Inc.